TRVI · Trevi Therapeutics, Inc.
$17.54
+1.71% last session
End-of-day data · updated 2026-07-28
Market cap
$3B
Enterprise value
$2B
Trailing P/E
—
Forward P/E
-32.5
Dividend yield
—
Beta
1.00
Avg volume
2M
Employees
0K
2D change
—
5D change
5.47%
10D change
-4.98%
30D change
-0.17%
60D change
28.15%
MTD change
2.90%
YTD change
44.73%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — TRVI
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-07-21
Latest call per bank · past 12 months
Morgan Stanley
Overweight$18.00
+2.6% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-21 | BMO Capital | Initiates | Outperform | $0.00 → $36.00 |
| 2026-07-20 | B. Riley Securities | Maintains | Buy | $21.00 → $31.00 |
| 2026-07-20 | HC Wainwright & Co. | Maintains | Buy | $21.00 → $24.00 |
| 2026-05-20 | Needham | Reiterates | Buy | $23.00 |
| 2026-05-06 | HC Wainwright & Co. | Reiterates | Buy | $21.00 |
| 2026-05-06 | Needham | Maintains | Buy | $24.00 → $23.00 |
| 2026-04-17 | D. Boral Capital | Maintains | Buy | $19.00 |
| 2026-03-19 | Jones Trading | Maintains | Buy | $25.00 → $24.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 55 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 14.5% above the 50-day MA ($16.09).
- Price vs 200-day MA: Trading 41.9% above the 200-day MA ($12.99).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-0.12) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($7.01) and high ($19.50).
TRVI Price Chart
Loading chart for TRVI…
Fundamentals
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough. Trevi Therapeutics, Inc. has a license agreement with Keenova Therapeutics plc to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. Trevi Therapeutics, Inc. was incorporated in 2011 and is headquartered in New Haven, Connecticut.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$122B 5.7% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$70B -13.3% YTD
ARGX
argenx SE
$56B 5.7% YTD
RVMD
Revolution Medicines, Inc.
$40B 136.1% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$37B -30.0% YTD
ONC
BeOne Medicines Ltd.
$34B 7.3% YTD
RPRX
Royalty Pharma plc
$34B 53.5% YTD
ROIV
Roivant Sciences Ltd.
$25B 60.0% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.